ADDC - AstraZeneca Collaboration

Areas Of Interest
Cardiovascular & Metabolic Disease (CVMD)
  • Heart failure and cardiac regeneration
  • Diabetic islet cell health, insulin sensitisation, and the return of beta cell function
  • Nephropathy
  • Dyslipidaemia, atherosclerosis and chronic heart disease
  • NASH (non-alcoholic steato hepatitis)
  • Chronic kidney disease and diabetic nephropathy
Oncology
  • Lung cancer
  • Haematological malignancies
  • Breast cancer
  • Ovarian cancer
  • Immune mediated therapies
  • Genetic and molecular targeting
  • DNA damage repair
  • Antibody-drug conjugates
  • Biologically-synergistic combinations
Neuroscience
  • Neurodegenerative disorders
  • Neurodevelopmental disorders
  • Chronic analgesia

For more information on Partnering With AstraZeneca https://www.astrazeneca.com/Partnering.html

Time Line
Fall 2018
Now accepting submissions for 2018. Deadline November 9th, 2018.
Fall 2018
Results anticipated December, 2018
DOWNLOAD RFP